# US 2025/0367194 A1 · Compositions and methods of use for modified release minoxidil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367194 A1
- Document ID: US20250367194A1
- Status: Published application
- Kind: A1
- Application number: 19/215,242
- Filed: 2025-05-21
- Published: 2025-12-04
- Earliest claimed: 2022-10-25
- Assignees: Veradermics Incorporated
- Applicants: Veradermics, Incorporated
- Inventors: Reid WALDMAN
- Web page: https://patentgrep.com/patent/US20250367194A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61P 17/14: for baldness or alopecia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating hair loss, comprising orally administering a dosage form to a human being experiencing hair loss, wherein the dosage form comprises about 4.5 mg of minoxidil or a molar equivalent amount of the pharmaceutically acceptable salt thereof, and about 65% to about 85% of hydroxypropyl methylcellulose by weight of the dosage form.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosage form is administered once daily.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dosage form is administered twice daily.

### Claim 4 (depends on 1)

The method of claim 1, wherein the hydroxypropyl methylcellulose provides modified release of the minoxidil, and orally administering the dosage form provides an AUC0-inf that is less than the AUC0-inf provided by a dosage form containing an immediate release formulation of 4.5 mg of minoxidil.

### Claim 5 (depends on 1)

The method of claim 1, wherein a blood level of minoxidil or the pharmaceutically acceptable salt thereof of about 1 ng/ml to about 20 ng/ml is maintained for at least about 8 hours.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage form further comprises a filler, a glidant, a lubricant, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the hair loss comprises female pattern hair loss.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hair loss comprises hereditary hair loss.

### Claim 9 (depends on 1)

The method of claim 1, wherein the hair loss comprises telogen effluvium.

### Claim 10 (depends on 1)

The method of claim 1, wherein the hair loss comprises alopecia areata.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hair loss comprises central centrifugal cicatricial alopecia.

### Claim 12 (depends on 1)

The method of claim 1, wherein the hair loss comprises lichen planopilaris.

### Claim 13 (depends on 1)

The method of claim 1, wherein the hair loss comprises traction alopecia.

### Claim 14 (depends on 1)

The method of claim 1, wherein the oral administration results in hair regrowth.

### Claim 15 (depends on 1)

The method of claim 1, wherein the dosage form comprises an enteric coating.

### Claim 16 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no tachycardia.

### Claim 17 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no symptomatic hypotension.

### Claim 18 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no premature ventricular contractions.

### Claim 19 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no symptomatic tachyarrhythmias.

### Claim 20 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no peripheral edema.

### Claim 21 (depends on 1)

The method of claim 1, wherein the oral administration of the dosage form results in no lightheadedness.
